Sławomir Jeka

Publications

• 1.88

  Impact points

  Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT): 10-year follow-up.

  Mariusz Korkosz, Jerzy Gąsowski, Piotr Grzanka, Janusz Gorczowski, Wojciech Pluskiewicz, Sławomir Jeka, Tomasz Grodzicki

  BMC musculoskeletal disorders. 01/2011; 12:121.

  To evaluate the relationship between bone loss and new bone formation in ankylosing spondylitis (AS) using 10-year X-ray, dual-energy x-ray absorptiometry (DXA) and quantitative computed tomography (QCT) follow-up. Fifteen AS patients free from medical conditions and drugs affecting bone metabolism ... [more] To evaluate the relationship between bone loss and new bone formation in ankylosing spondylitis (AS) using 10-year X-ray, dual-energy x-ray absorptiometry (DXA) and quantitative computed tomography (QCT) follow-up. Fifteen AS patients free from medical conditions and drugs affecting bone metabolism underwent X-ray, DXA and QCT in 1999 and 2009. In spine QCT a statistically significant (p = 0,001) decrease of trabecular bone mineral content (BMC) was observed (change ± SD: 18.0 ± 7.3 mg/cm3). In contrast, spine DXA revealed a significant increase of bone mineral density (change ± SD: -0.15 ± 0.14 g/cm2). The mean BMC, both at baseline and follow-up was significantly lower (p = 0.02 and p = 0.005, respectively) in advanced radiological group as compared to early radiological group. However, in multiple regression model after adjustment for baseline BMC, the baseline radiological scoring did not influence the progression of bone loss as assessed with QCT (p = 0.22, p for BMC*X-ray syndesmophyte scoring interaction = 0.65, p for ANOVA-based X-ray syndesmophyte scoring*time interaction = 0.39). Baseline BMC was the only significant determinant of 10-year BMC change, to date the longest QCT follow-up data in AS. In AS patients who were not using antiosteoporotic therapy spine trabecular bone density evaluated by QCT decreased over 10-year follow-up and was not related to baseline radiological severity of spine involvement.
• 0.57

  Impact points

  [Recurrent cardiac tamponade and sepsis in a patient with rheumatoid arthritis].

  Wojciech Balak, Władysław Sinkiewicz, Sławomir Jeka, Joanna Banach, Anna Sinkiewicz, Danuta Karasek, Jan Błażejewski, Robert Bujak

  Kardiologia polska. 01/2011; 69(9):948-50; discussion 951.

  Exudative pericarditis is found in 30-50% of the patients with rheumatoid arthritis (RA), particularly in later stages of the disease. Most cases present with no or few symptoms. We report a case of a 68 year-old male with a history of mild RA who developed exudative pericarditis leading to recurren... [more] Exudative pericarditis is found in 30-50% of the patients with rheumatoid arthritis (RA), particularly in later stages of the disease. Most cases present with no or few symptoms. We report a case of a 68 year-old male with a history of mild RA who developed exudative pericarditis leading to recurrent cardiac tamponade requiring repeated pericardiocenteses. Treatment with glucocorticosteroids, methotrexate and colchicine proved ineffective in preventing the recurrences. Immunosuppression contributed to the development of sepsis caused by Enterobacter cloacae and resulting in the patient's death.

• [Modern ultrasonographic techniques for the study of the synovial membrane in rheumatic diseases].

  Sławomir Jeka, Elzbieta Sokólska, Piotr Ignaczak, Marta Dura

  Annales Academiae Medicae Stetinensis. 01/2010; 56 Suppl 1:16-24.

  In recent years ultrasonography has become one of basic imaging techniques used by radiologists, orthopedists, and rheumatologists for the study of the musculoskeletal system, particularly in patients with rheumatic diseases. This position of ultrasonography is the result of rapid technical advances... [more] In recent years ultrasonography has become one of basic imaging techniques used by radiologists, orthopedists, and rheumatologists for the study of the musculoskeletal system, particularly in patients with rheumatic diseases. This position of ultrasonography is the result of rapid technical advances. Contemporary ultrasound scanners have little in common with those used when ultrasonography was introduced into medicine. Modern ultrasound scanners offer additional options like tissue harmonic imaging, power color Doppler, volumetric ultrasonography (3D/4D imaging), and contrast-enhanced ultrasonography. Moreover, image resolution during examination has significantly been improved thanks to high-resolution transducers and software for image analysis. This article discusses modern ultrasonographic techniques and their use.
• 2.79

  Impact points

  Safety and tolerability of short-term preventive frovatriptan: a combined analysis.

  E Anne MacGregor, Jan L Brandes, Stephen Silberstein, Slawomir Jeka, Piotr Czapinski, Bob Shaw, Stephen Pawsey

  Headache. 10/2009; 49(9):1298-314.

  OBJECTIVE: To assess the safety and tolerability profile of the 5-HT(1B/1D) agonist frovatriptan (Frova(R), Endo Pharmaceuticals Inc., Chadds Ford, PA, USA) when used as a 6-day regimen for the short-term prevention of menstrual migraine scheduled over multiple perimenstrual periods. BACKGROUND: Two... [more] OBJECTIVE: To assess the safety and tolerability profile of the 5-HT(1B/1D) agonist frovatriptan (Frova(R), Endo Pharmaceuticals Inc., Chadds Ford, PA, USA) when used as a 6-day regimen for the short-term prevention of menstrual migraine scheduled over multiple perimenstrual periods. BACKGROUND: Two randomized controlled trials have established the efficacy of a 6-day regimen of frovatriptan for reducing the incidence and severity of menstrual migraine over 1 to 3 perimenstrual periods; long-term data are needed to further assess the safety and tolerability profile of this regimen. METHODS: Two multinational trials were included in the analysis: Study 1 was a randomized, placebo-controlled double-blind parallel trial (3 perimenstrual periods treated) with an open-label extension (3 additional perimenstrual periods treated), and Study 2 was a long-term (12 perimenstrual periods treated over 12-15 months) open-label study. Enrolled women experienced menstrual migraine defined as predictable migraine attacks that started -2 days to +3 (Study 1) or +4 (Study 2) days relative to the first day of menses and that occurred in at least 2 out of 3 menstrual cycles. Frovatriptan or placebo was given 2 days before anticipated menstrual migraine and continued for 6 days. Adverse events, serious adverse events, vital signs, cardiovascular events, electrocardiograms, and laboratory parameters were assessed and recorded periodically and summarized using descriptive statistics. Adverse event data from Study 1 and Study 2 were compared using event rates. RESULTS: The demographic characteristics of the 2 study populations were similar: the mean age was approximately 38 years, > or =94% of participants were white, and 85% reported menstrual migraine began on days -2 to +1 of the menstrual cycle. The mean reported history of menstrual migraine was approximately 11 years. A large percentage of the respective safety populations completed each study or study period: 87% (362/416) and 88% (273/309) completed the double-blind period and open-label periods of Study 1, respectively, and 59% (308/525) completed treatment of 12 perimenstrual periods in Study 2. Major reasons for discontinuation in Study 1 included adverse events (5%, double-blind period) and "other" (10% double-blind period and 5% open-label period). In Study 2, major reasons for discontinuation included patient request (17.3%) and adverse event (10.2%). The most common treatment emergent adverse events in the double-blind period of Study 1 (placebo vs frovatriptan twice daily) were upper respiratory infection (9% vs 9%), nausea (6% vs 8%), dizziness (7% vs 7%), fatigue (4% vs 7%), dysmenorrhea (3% vs 7%), influenza (3% vs 6%), neck pain (4% vs 6%), and migraine (4% vs 4%). With the exception of migraine (which was reported using a different method in each study), prevalence rates for Studies 1 and 2 were numerically similar. The most frequently reported cardiovascular adverse events during double-blind treatment (placebo vs frovatriptan twice daily) were chest discomfort (2% and 3%), chest pain (2% and 2%), and hypertension (0 and 2%). The corresponding adverse event rates in Study 2 were 2% (chest pain), 3% (chest discomfort), and 3% (hypertension). In both studies, most adverse events were of mild or moderate intensity and their incidence numerically declined with each perimenstrual period/cycle, as did the incidence of menstrual migraine. The observed rate of intercurrent migraine in Study 2 over 12 perimenstrual periods was 1.5 per month, compared with 1.7 at baseline. There was no observable increase in the first occurrence of migraine in the 5 days following the perimenstrual period, indicating a lack of rebound headache. CONCLUSIONS: During treatment of up to 12 perimenstrual periods over a 12- to 15-month period, the safety and tolerability of frovatriptan for short-term prevention of menstrual migraine was similar to that observed with acute use of triptans. Adverse events were generally mild or moderate in severity, there was no evidence of an increased risk of cardiovascular adverse events relative to acute treatment, and rebound headache was not evident. A short-term regimen with frovatriptan presents a safe and viable treatment option for preventing predictable migraine such as menstrual migraine.
• 2.25

  Impact points

  Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab.

  Beata Nowak, Sławomir Jeka, Piotr Wiland, Jacek Szechiński

  Joint, bone, spine : revue du rhumatisme. 03/2009;

• [Endoparasite twin (fetus in fetu)]

  Władimir Boziłow, Witold Malinowski, Zbigniew Klempous, Sławomir Jeka

  Ginekologia polska. 04/2005; 76(3):228-33.

  Fetus in fetu is a very rare abnormality (estimated incidences: 1 in 500,000 deliveries), and is secondary to a pathological diamniotic monochorionic pregnancy. It consists of a malformed parasitic twin that is found within the body of its sibling. Hardly 70 cases have been reported in the literatur... [more] Fetus in fetu is a very rare abnormality (estimated incidences: 1 in 500,000 deliveries), and is secondary to a pathological diamniotic monochorionic pregnancy. It consists of a malformed parasitic twin that is found within the body of its sibling. Hardly 70 cases have been reported in the literature since its first description about 1800. Its discovery is usually postnatal. We present two boys: two and half years and eleven days old newborn presented a mass in the retroperitoneum in the left upper abdominal quadrant. There were removed by surgery and contained two independent fetuses. Dissection and radiological study of the fetuses showed an axial skeleton and long bones. It corresponds to the generally recognized diagnostic criteria of fetus in fetu. The embryology, operative procedure, hypothesis and pathology of this condition are discussed and the literature briefly reviewed. The difference between teratomas and fetus in fetu is point.

• [Transvaginal ultrasonography and sonohysterography in the diagnosis of benign uterine lesions in women at peri- and postmenopausal age]

  Władysław Lasek, Marian Migda, Stanisław Pilecki, Zbigniew Serafin, Sławomir Jeka, Joanna Rosińska-Migda

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 08/2004; 17(97):47-9.

  Abnormal uterine bleeding is important clinical problem in women at peri- and postmenopausal age. It may be caused by the lesions located in endometrium or in deeper uterine wall layers. An aim of this paper was a comparison of transvaginal sonography (TVS) vs. sonohysterography (SIS) in the diagnos... [more] Abnormal uterine bleeding is important clinical problem in women at peri- and postmenopausal age. It may be caused by the lesions located in endometrium or in deeper uterine wall layers. An aim of this paper was a comparison of transvaginal sonography (TVS) vs. sonohysterography (SIS) in the diagnostics of endometrial polyps, endometrial hyperplasia as well as uterine myomas. Also the results of the sonographic imaging were compared to those of pathologic examination of the specimens taken from the uterine cavity. The material consisted of 100 women aged 40-80 with an irregular menstruation. All of the patients were examined gynecologically, and then the transvaginal sonography, sonohysterography and the curettage of the uterine cavity were performed. Sensitivity of TVS was 43% in endometrial polyps, 77% in endometrial hyperplasia and 69% in uterine myomas imaging. Introduction of SIS increased the sensitivity to 94%, 82%, and 95%, respectively. Specificity was similar in both techniques except endometrial hyperplasia (TVS--68%, SIS--91%). Diagnostic accuracy also improved with the SIS use reaching 93% for polyps, 89% for hyperplasia and 98% for myomas imaging. Our results show higher sensitivity and accuracy of SIS in the diagnostic of benign uterine lesions.